Latest Oblique Therapeutics News & Updates

See the latest news and media coverage for Oblique Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Oblique Therapeutics

Biotech developing antibodies for pain and cancer

obliquet.com

Headquarters: Göteborg, Sweden
Founded year: 2015
Company type: Private company
Number of employees: 5–10
Industry: Pharmaceuticals

Last updated Today

Latest news about Oblique Therapeutics

In short: Oblique Therapeutics secured multiple funding rounds through rights issues and convertibles while expanding its strategic R&D partnerships.

Company announcements

April 30 Oblique Therapeutics

Oblique Therapeutics announces conversion of mandatory convertibles

Convertibles of 15.8 MSEK are converted to 10.5 million new A-shares, increasing the number of shares to 56.2 million with 18.77% dilution.

7 July 2025 Oblique Therapeutics

Oblique Therapeutics announces the outcome of the convertible bond issue

The issue was subscribed to 95.4% of 14.5 MSEK. Convertibles are converted in 2026 to shares with 25.6% dilution.

24 June 2025 Oblique Therapeutics

Oblique Therapeutics publishes supplementary prospectus

The addition is approved by the Financial Supervisory Authority due to errors in the conversion rates. Investors can withdraw their subscription until 25 June 2025.

13 June 2025 Oblique Therapeutics

Oblique Therapeutics postpones the subscription period in the convertible issue

The reason is the delayed registration of the prospectus with the Financial Supervisory Authority. The terms are unchanged except for the maturity.

Media coverage

June 30 Yahoo Finance

Oblique Therapeutics AB Announces Outcome of Rights Issue of SEK 14.1 Million

Oblique Therapeutics AB ("Oblique" or the "Company") today announces the outcome of the rights issue that closed on June 30. The rights issue was fully...

April 30 Dagens industri

Oblique Therapeutics announces conversion of mandatory convertibles

The board of directors of Oblique Therapeutics AB (publ) ("Oblique Therapeutics" or "the Company") announces that all convertibles issued within the framework of...

11 June 2025 Dagens industri

Oblique Therapeutics announces today that the company has carried out a targeted cost reduction

"We have carried out necessary and structural changes to optimize our capital use and at the same time ensure that we fully prioritize what has the greatest value creation...

3 June 2025 Dagens industri

Oblique Therapeutics carries out an issue of convertibles of approximately 15.2 MSEK primarily directed to existing shareholders

Oblique Therapeutics has developed a patented technology, AbiProt®, with which one can identify areas on target proteins in the cell membrane where antibodies can bind. Information regarding these...

Never miss news about Oblique Therapeutics

Track Oblique Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Oblique Therapeutics competitors & trending companies

Browse news for competitors to Oblique Therapeutics and other trending companies.